Demand for CAR-T therapies is growing faster than the supply chain’s ability to keep up. In the near- to mid-term, the patients who need these therapies the most are more likely to face long waits. However, there are some potential solutions to these manufacturing and supply chain bottlenecks. In this paper, we address several of the potential solutions that are most commonly cited, offering a brief explanation of each and what we think the future might hold.
We explore:
- “Rapid manufacturing” techniques
- Decoupling cell therapy production from viral vectors
- Allogeneic cell therapies
- Increased automation
